To develop and validate the Myotonic Dystrophy Type 2 Health Index (MD2HI), a disease-specific, patient-reported outcome (PRO) measure for use in myotonic dystrophy type 2 (DM2) therapeutic trials and clinical monitoring.
No takes yet. Share an insight, caveat, or question.
Engebrecht et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: